Top Markets
#1 DogBull DogBull +108.53%
#2 MarsCoin MarsCoin +84.53%
#3 Siacoin Siacoin +54.30%
#4 ADO Protocol ADO Protocol +52.61%
#5 The Bitcoin Bull The Bitcoin Bull +28.19%
#6 Ontology Gas Ontology Gas +26.26%
#7 Apertum Apertum +16.17%
#8 Useless Coin Useless Coin +13.13%
#9 Arowana Arowana +12.73%
#10 Pons Pons +12.09%
Coin of the day
DogBull DogBull
Innstillinger
Språk
NORSK
Valuta
USD
Tema
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPT
Rangering i aksjer #15062
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the... EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Aksjekurs
$4.48
Sist synkronisert: 2026-08-31
Markedsverdi
$375.37M
Endring (1 dag)
-0.06%
Endring (1 år)
-61.30%
Land
US
Handel EyePoint Pharmaceuticals, Inc. (EYPT)

Kategori

Healthcare
P/E-forhold for EyePoint Pharmaceuticals, Inc. (EYPT)
P/E-forhold per 2026 TTM: 0
Ifølge EyePoint Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for EyePoint Pharmaceuticals, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.